Larotrectinib sulfate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for larotrectinib sulfate and what is the scope of patent protection?
Larotrectinib sulfate
is the generic ingredient in one branded drug marketed by Bayer Hlthcare and Bayer Healthcare, and is included in two NDAs. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Larotrectinib sulfate has two hundred and thirty patent family members in fifty countries.
Two suppliers are listed for this compound.
Summary for larotrectinib sulfate
International Patents: | 230 |
US Patents: | 18 |
Tradenames: | 1 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 43 |
Clinical Trials: | 4 |
Patent Applications: | 126 |
DailyMed Link: | larotrectinib sulfate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for larotrectinib sulfate
Generic Entry Dates for larotrectinib sulfate*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
Generic Entry Dates for larotrectinib sulfate*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for larotrectinib sulfate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
M.D. Anderson Cancer Center | Phase 2 |
Children's Oncology Group | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
Pharmacology for larotrectinib sulfate
Drug Class | Kinase Inhibitor |
Mechanism of Action | Tropomyosin Receptor Kinases Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for larotrectinib sulfate
US Patents and Regulatory Information for larotrectinib sulfate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 8,865,698 | ⤷ Subscribe | ⤷ Subscribe | ||||
Bayer Healthcare | VITRAKVI | larotrectinib sulfate | SOLUTION;ORAL | 211710-001 | Nov 26, 2018 | RX | Yes | Yes | 10,774,085 | ⤷ Subscribe | ⤷ Subscribe | ||||
Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-001 | Nov 26, 2018 | RX | Yes | No | 10,172,861 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for larotrectinib sulfate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2350071 | COMPOSÉS DE PYRAZOLO[1,5-A]PYRIMIDINE SUBSTITUÉS COMME INHIBITEURS DE LA TRK KINASE (SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS) | ⤷ Subscribe |
Tunisia | 2018000338 | METHODS OF TREATING PEDIATRIC CANCERS | ⤷ Subscribe |
Japan | 2021169496 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for larotrectinib sulfate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3106463 | C20200005 00308 | Estonia | ⤷ Subscribe | PRODUCT NAME: LAROTREKTINIIB;REG NO/DATE: EU/1/19/1385; 23.09.2019 |
3106463 | C202030011 | Spain | ⤷ Subscribe | PRODUCT NAME: LAROTRECTINIB Y/O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, PARTICULARMENTE SULFATO DE LAROTRECTINIB QUE INCLUYE HIDROGENOSULFATO DE LAROTRECTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1385; DATE OF AUTHORISATION: 20190919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1385; DATE OF FIRST AUTHORISATION IN EEA: 20190919 |
3106463 | 2090009-8 | Sweden | ⤷ Subscribe | PRODUCT NAME: LAROTRECTINIB,OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY LAROTRECTINIB SULFATE INCLUDING LAROTRECTINIB HYDROGEN SULFATE; REG. NO/DATE: EU/1/19/1385 20190923 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Larotrectinib sulfate Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.